Skip to main content
Top

Drugs

Issue 8/2016

Content (9 Articles)

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

  • Current Opinion

Raffaele Califano, Ourania Romanidou, Giannis Mountzios, Lorenza Landi, Federico Cappuzzo, Fiona Blackhall

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

  • Therapy in Practice

Philippe Moreau, Niels W. C. J. van de Donk, Jesus San Miguel, Henk Lokhorst, Hareth Nahi, Dina Ben-Yehuda, Michele Cavo, Gordon Cook, Michel Delforge, Hermann Einsele, Sonja Zweegman, Heinz Ludwig, Christoph Driessen, Antonio Palumbo, Thierry Facon, Torben Plesner, Meletios Dimopoulos, Pia Sondergeld, Pieter Sonneveld, María-Victoria Mateos

Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia

  • Adis Drug Evaluation

Celeste B. Burness, Gillian M. Keating, Karly P. Garnock-Jones

Gabapentin Enacarbil: A Review in Restless Legs Syndrome

  • Adis Drug Evaluation

Esther S. Kim, Emma D. Deeks

Ixekizumab: First Global Approval

  • AdisInsight Report

Anthony Markham

Reslizumab: First Global Approval

  • AdisInsight Report

Anthony Markham

Erratum to: Management Strategies for Clopidogrel Hypersensitivity

  • Erratum

Craig J. Beavers, Nicolas W. Carris, Kathryn M. Ruf

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images